New markers in metabolic syndrome

Da Hye Son; Hyun Su Ha; Hye Min Park; Hae Young Kim; Yong Jae Lee

doi:10.1016/bs.acc.2022.06.002

New markers in metabolic syndrome

Da Hye Son, Hyun Su Ha, Hye Min Park, Hae Young Kim, Yong Jae Lee

Department of Family Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Citation (Scopus)

Abstract

Metabolic syndrome (MetS) is increasing globally and is clinically significant due to its association with cardiovascular disease, type 2 diabetes and cancer. Although the pathogenesis of MetS has not been clearly elucidated, insulin resistance and chronic low-grade inflammation derived from central obesity are the most widely accepted as underlying pathophysiology. Accordingly, insulin resistance indices, adipokines and various inflammatory markers have been suggested as reliable biomarkers for MetS. Others, such as uric acid, alkaline phosphatase, γ-glutamyl transferase, are also known to positively correlate with MetS and could be diagnostically useful. In this review, we provide a comprehensive overview of MetS biomarkers and the development of a systematic approach to laboratory analysis.

Original language	English
Title of host publication	Advances in Clinical Chemistry
Editors	Gregory S. Makowski, Gregory S. Makowski
Publisher	Academic Press Inc.
Pages	37-71
Number of pages	35
ISBN (Print)	9780323988537
DOIs	https://doi.org/10.1016/bs.acc.2022.06.002
Publication status	Published - 2022 Jan

Publication series

Name	Advances in Clinical Chemistry
Volume	110
ISSN (Print)	0065-2423
ISSN (Electronic)	2162-9471

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Chemistry(all)
Clinical Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/bs.acc.2022.06.002

Cite this

@inbook{fbee7b3305ae4d2b8c38cabda8768a36,

title = "New markers in metabolic syndrome",

abstract = "Metabolic syndrome (MetS) is increasing globally and is clinically significant due to its association with cardiovascular disease, type 2 diabetes and cancer. Although the pathogenesis of MetS has not been clearly elucidated, insulin resistance and chronic low-grade inflammation derived from central obesity are the most widely accepted as underlying pathophysiology. Accordingly, insulin resistance indices, adipokines and various inflammatory markers have been suggested as reliable biomarkers for MetS. Others, such as uric acid, alkaline phosphatase, γ-glutamyl transferase, are also known to positively correlate with MetS and could be diagnostically useful. In this review, we provide a comprehensive overview of MetS biomarkers and the development of a systematic approach to laboratory analysis.",

author = "Son, {Da Hye} and Ha, {Hyun Su} and Park, {Hye Min} and Kim, {Hae Young} and Lee, {Yong Jae}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = jan,

doi = "10.1016/bs.acc.2022.06.002",

language = "English",

isbn = "9780323988537",

series = "Advances in Clinical Chemistry",

publisher = "Academic Press Inc.",

pages = "37--71",

editor = "Makowski, {Gregory S.} and Makowski, {Gregory S.}",

booktitle = "Advances in Clinical Chemistry",

address = "United States",

}

TY - CHAP

T1 - New markers in metabolic syndrome

AU - Son, Da Hye

AU - Ha, Hyun Su

AU - Park, Hye Min

AU - Kim, Hae Young

AU - Lee, Yong Jae

PY - 2022/1

Y1 - 2022/1

N2 - Metabolic syndrome (MetS) is increasing globally and is clinically significant due to its association with cardiovascular disease, type 2 diabetes and cancer. Although the pathogenesis of MetS has not been clearly elucidated, insulin resistance and chronic low-grade inflammation derived from central obesity are the most widely accepted as underlying pathophysiology. Accordingly, insulin resistance indices, adipokines and various inflammatory markers have been suggested as reliable biomarkers for MetS. Others, such as uric acid, alkaline phosphatase, γ-glutamyl transferase, are also known to positively correlate with MetS and could be diagnostically useful. In this review, we provide a comprehensive overview of MetS biomarkers and the development of a systematic approach to laboratory analysis.

AB - Metabolic syndrome (MetS) is increasing globally and is clinically significant due to its association with cardiovascular disease, type 2 diabetes and cancer. Although the pathogenesis of MetS has not been clearly elucidated, insulin resistance and chronic low-grade inflammation derived from central obesity are the most widely accepted as underlying pathophysiology. Accordingly, insulin resistance indices, adipokines and various inflammatory markers have been suggested as reliable biomarkers for MetS. Others, such as uric acid, alkaline phosphatase, γ-glutamyl transferase, are also known to positively correlate with MetS and could be diagnostically useful. In this review, we provide a comprehensive overview of MetS biomarkers and the development of a systematic approach to laboratory analysis.

UR - http://www.scopus.com/inward/record.url?scp=85134814010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134814010&partnerID=8YFLogxK

U2 - 10.1016/bs.acc.2022.06.002

DO - 10.1016/bs.acc.2022.06.002

M3 - Chapter

C2 - 36210076

AN - SCOPUS:85134814010

SN - 9780323988537

T3 - Advances in Clinical Chemistry

SP - 37

EP - 71

BT - Advances in Clinical Chemistry

A2 - Makowski, Gregory S.

PB - Academic Press Inc.

ER -

New markers in metabolic syndrome

Abstract

Publication series

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this